Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Infliximab/mesalazine/ustekinumab

Lack of efficacy and psoriasis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Dai C, et al. Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab. Revista Espanola de Enfermedades Digestivas 116: 176-177, No. 3, Mar 2024. Available from: URL: https://dx.doi.org/10.17235/reed.2023.9745/2023 Dai C, et al. Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab. Revista Espanola de Enfermedades Digestivas 116: 176-177, No. 3, Mar 2024. Available from: URL: https://​dx.​doi.​org/​10.​17235/​reed.​2023.​9745/​2023
Metadaten
Titel
Infliximab/mesalazine/ustekinumab
Lack of efficacy and psoriasis
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55618-y

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Levamisole

Case report

Peginterferon